Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

tax adjustments primarily related to changes in valuation allowances, the settlement of the investigations by the U.S. Attorney's Office and other changes in tax assets and liabilities. The 2008 amount includes $84.5 million of tax benefits for the settlement with the U.S. Attorney's Office, for which the related expense was recorded in 2007 and for the states of Connecticut and Massachusetts, for which the related expense was recorded in the third quarter of 2008.

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of GAAP Net Income to Adjusted Net Income

(Unaudited)

Nine Months Ended

September 30,

2008 2007

GAAP NET (LOSS) INCOME $210,962 $(235,886)

Cost of sales adjustments 111,349 (1) 64,236 (1)

Research and development adjustments 8,013 (2) 41,500 (2)

Selling, general and administrative

adjustments 30,124 (3) -

Settlement reserve 7,450 (4) 425,000 (4)

Gain on sale of investment - (5,791) (5)

Gain on extinguishment of debt - (5,319) (6)

Interest expense adjustment 11,250 (7)

Restructuring charges 6,973 (8)

In-process research and development 10,000 (9)

Income tax adjustment (143,162) (10) (40,459) (10)

41,997 479,167

ADJUSTED NET INCOME $252,959 $243,281

BASIC ADJUSTED INCOME PER COMMON

SHARE $3.73 $3.66

DILUTED ADJUSTED INCOME PER COMMON

SHARE
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)...   Mapi expands Pharmacovigilance and Risk ... global Risk Management strength with the expanded breadth ... . Pharmacovigilance and Risk ... team that includes physicians, pharmacists, and numerous other ... navigating complex safety requirements throughout the product lifecycle. ...
(Date:3/31/2015)...  University of Illinois, Swanlund ... plenary session address on Monday, May 18 at the ... kicking off a week of more than 160 technical ... RF and microwave technologies with health. Dr. ... Circuits for the Skin," will focus on the experimental ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Diasome Pharmaceuticals, ... licensor, SDG, Inc., that a United States patent has ... insulin therapy. , Entitled “Lipid Construct for ... composition of matter claims related to the use of ... for enabling injected insulin to more effectively reach the ...
(Date:3/30/2015)... Winston-Salem, NC (PRWEB) March 30, 2015 ... Associates are pleased to announce the formation of ... clinical research centers specializing in the conduct of ... populations. VaxCorps clinical sites have successfully conducted ... extensive experience in seasonal and pandemic influenza as ...
Breaking Biology Technology:Mapi expands Pharmacovigilance and Risk Management capabilities 2Mapi expands Pharmacovigilance and Risk Management capabilities 3Health and Engineering Converge at the 2015 International Microwave Symposium 2Health and Engineering Converge at the 2015 International Microwave Symposium 3Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2
... 6%; Clinical Diagnostics Grows 9.4%; On Target to ... Achieve Full Year ... BEC ), a leading developer, manufacturer and marketer of,products that simplify, ... 30, 2007 results. Total,revenue of $669 million was up 6.0% over ...
... The University of Texas at San Antonio and The ... research universities in a nationwide consortium awarded $1.4 million ... Research Team (NIRT) grant is designed to explore ways ... and develop means of controlling optical energy for applications ...
... Pharmaceuticals,Inc. (Nasdaq: AMLN ) will be presenting at ... 9:30 a.m. PT in San Diego. Daniel M.,Bradbury, President ... a corporate overview. The live presentation will be ... event. The webcast and recording will be accessible,through Amylin,s ...
Cached Biology Technology:Beckman Coulter Announces Third Quarter 2007 Results 2Beckman Coulter Announces Third Quarter 2007 Results 3Beckman Coulter Announces Third Quarter 2007 Results 4Beckman Coulter Announces Third Quarter 2007 Results 5Beckman Coulter Announces Third Quarter 2007 Results 6Beckman Coulter Announces Third Quarter 2007 Results 7Beckman Coulter Announces Third Quarter 2007 Results 8Beckman Coulter Announces Third Quarter 2007 Results 9Beckman Coulter Announces Third Quarter 2007 Results 10Beckman Coulter Announces Third Quarter 2007 Results 11Beckman Coulter Announces Third Quarter 2007 Results 12Beckman Coulter Announces Third Quarter 2007 Results 13Beckman Coulter Announces Third Quarter 2007 Results 14Beckman Coulter Announces Third Quarter 2007 Results 15Beckman Coulter Announces Third Quarter 2007 Results 16Beckman Coulter Announces Third Quarter 2007 Results 17Beckman Coulter Announces Third Quarter 2007 Results 18Beckman Coulter Announces Third Quarter 2007 Results 19Beckman Coulter Announces Third Quarter 2007 Results 20Beckman Coulter Announces Third Quarter 2007 Results 21Beckman Coulter Announces Third Quarter 2007 Results 22Beckman Coulter Announces Third Quarter 2007 Results 23Beckman Coulter Announces Third Quarter 2007 Results 24Beckman Coulter Announces Third Quarter 2007 Results 25UTSA/UT lead national nanoscience consortium 2
(Date:3/11/2015)... and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) has announced ... Product, Application & By Geography - Global Forecast & ... This report predicts that the access control ... with an estimated CAGR of 10.6%. The ... as contact cards & readers, contactless cards & readers, ...
(Date:3/10/2015)...   Tute Genomics , pioneer in affordable, accurate ... sequencing company PrimBio Research Institute to be ... panel interpretation. PrimBio, a certified Life Technologies ... technologies to support the work of experts on the ... types of exome sequencing services: 1) Targeted Exome and ...
(Date:3/3/2015)... LAKE FOREST, Calif. , March 3, ... ("Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, today announced the ... Hutchinson Cancer Research Centers, ("Fred Hutch") ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... will look at possible health effects of the Gulf of ... volunteers begins today in towns across Louisiana, Mississippi, Alabama, and ... is the largest health study of its kind ever conducted ... a comprehensive federal response to the Deepwater Horizon oil spill. ...
... in Temple University,s College of Science and Technology has ... leptin receptor antagonist peptide, developed by researchers Laszlo Otvos ... triple negative breast cancer treatment, especially in the obese ... in the European Journal of Cancer . ...
... Benjamin Clough has developed a novel method ... plasma acoustic bursts. The doctoral student at Rensselaer ... employs sound waves to boost the distance from ... remotely detect hidden explosives, chemicals, and other dangerous ...
Cached Biology News:NIH launches largest oil spill health study 2New peptide could be effective treatment for triple negative breast cancer 2Student innovation at Rensselaer holds key to safer remote detection of dangerous materials 2Student innovation at Rensselaer holds key to safer remote detection of dangerous materials 3
... The Ph.D. Peptide Display Cloning System ... on the surface of bacteriophage M13 as ... between each displayed peptide and its encoding ... of targets can then be selected by ...
... Detection of the yolk protein Vtg in ... simple and sensitive biomarker for endocrine disrupting chemicals ... Vtg has become an accepted screening test for ... Vtg (rainbow trout) EIA kit is a double-antibody ...
... synthetic peptide whose sequence corresponds to residues 115-133 of rat SAP97. ... V115 - L - P - S - E - ... - P - N - E - V - L - ... added to facilitate conjugation and is not a part of the ...
... Rapid-Screen cDNA Library Panels were designed for ... sets of PCRs to identify the desired ... performed in a 96-well "Master Plate," where ... clones. Having identified the positive well(s) by ...
Biology Products: